Ticker Details
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals Inc is an integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
IPO Date:	April 2, 1991
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$85.87B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$4.74 | 1.89%
Avg Daily Range (30 D):	$10.93 | 1.51%
Avg Daily Range (90 D):	$9.90 | 1.44%

Institutional Daily Volume
Avg Daily Volume:	.67M
Avg Daily Volume (30 D):	.56M
Avg Daily Volume (90 D):	.68M

Trade Size
Avg Trade Size (Sh.):	58
Avg Trade Size (Sh.) (30 D):	20
Avg Trade Size (Sh.) (90 D):	21

Institutional Trades
Total Institutional Trades:	11,961
Avg Institutional Trade:	$20.41M
Avg Institutional Trade (30 D):	$60.39M
Avg Institutional Trade (90 D):	$56.55M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$40.28M
Avg Closing Trade (30 D):	$98.29M
Avg Closing Trade (90 D):	$120.06M
Avg Closing Volume:	78.1K

News

Aug 21, 2026 @ 11:02 AM IBBQ vs. PBE: Which Biotech ETF Is the Better Buy?... Source: Andy Gould

Aug 6, 2026 @ 12:34 AM Regeneron Pharmaceuticals, Inc. Investors with Sub... Source: Hagens Berman Sobol Shapiro Llp

Aug 4, 2026 @ 2:55 PM REGN Investors Have Opportunity to Lead Regeneron ... Source: The Schall Law Firm

Aug 4, 2026 @ 12:50 AM REGN ALERT: Hagens Berman Alerts Regeneron Pharmac... Source: Hagens Berman

Jul 31, 2026 @ 10:46 AM $REGN Securities: Suffer Losses on Your Regeneron ... Source: Bleichmar Fonti & Auld Llp

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$41.94	$12.62	$6.99
Diluted EPS	$40.47	$12.23	$6.75
Revenue	$15.53B	$4.29B	$3.61B
Gross Profit
Net Income / Loss	$4.33B	$1.3B	$727.2M
Operating Income / Loss	$3.84B	$1.29B	$642.9M
Cost of Revenue
Net Cash Flow	$450.4M	$-504.6M	$-153.1M
PE Ratio